Table 3.
Efficacy and safety studies of the direct oral anticoagulants in nonvalvular atrial fibrillation
| Dabigatran RE-LY | Rivaroxaban ROCKET-AF | Apixaban ARISTOTLE | Edoxaban ENGAGE AF | |
|---|---|---|---|---|
| N:Randomized | 18,113 | 14,264 | 18,201 | 21,105 |
| Mean age (years old) | 72 | 73 | 70 | 72 |
| Female (%) | 27 | 40 | 35 | 38 |
| Paroxysmal AF (%) | 32 | 18 | 15 | 25 |
| VKA naive (%) | 50 | 38 | 43 | 41 |
| Aspirin use (%) | 40 | 36 | 31 | 29 |
| Median TTR (%) | 66 | 58 | 66 | 68 |
| Mean CHADS2 Score | 2.1 | 3.5 | 2.1 | 2.8 |
| Efficacy: RR (95% CI) | 0.66 (0.53–0.82) | 0.80 (0.75–1.3) | 0.80 (0.67–0.95) | 0.88 (0.75–1.02) |
| Safety: RR (95% CI) | 0.93 (0.81–1.7) | 1.03 (0.96–1.11) | 0.69 (0.60–0.80) | 0.80 (0.71–0.90) |
| Efficacy | 150 mg: superior 110 mg: non-inferior |
Non-inferior | Superior | Non-inferior |
| Safety | 150 mg: non-inferior 110 mg: superior |
Non-inferior | Superior | Superior |
AF atrial fibrillation, CI confidence interval, RR relative risk, TTR time spent in therapeutic range, VKA vitamin K antagonist